Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $13.3 million.

  • Adma Biologics' Cash from Operations fell 4688.75% to $13.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.0 million, marking a year-over-year decrease of 2449.65%. This contributed to the annual value of $118.7 million for FY2024, which is 124854.55% up from last year.
  • As of Q3 2025, Adma Biologics' Cash from Operations stood at $13.3 million, which was down 4688.75% from $21.1 million recorded in Q2 2025.
  • Adma Biologics' Cash from Operations' 5-year high stood at $50.2 million during Q4 2024, with a 5-year trough of -$33.5 million in Q4 2021.
  • Its 5-year average for Cash from Operations is -$1.6 million, with a median of -$7.4 million in 2022.
  • Its Cash from Operations has fluctuated over the past 5 years, first soared by 85335.86% in 2024, then tumbled by 78706.04% in 2025.
  • Quarter analysis of 5 years shows Adma Biologics' Cash from Operations stood at -$33.5 million in 2021, then surged by 77.95% to -$7.4 million in 2022, then skyrocketed by 338.47% to $17.6 million in 2023, then soared by 185.37% to $50.2 million in 2024, then plummeted by 73.53% to $13.3 million in 2025.
  • Its last three reported values are $13.3 million in Q3 2025, $21.1 million for Q2 2025, and -$19.7 million during Q1 2025.